[Zimmer Biomet Holdings Q3 2026 Earnings Call] Zimmer Biomet Raises Full-Year Guidance on 3.7% Constant Currency Growth; Monogram Robot FDA Filing ‘Very, Very Soon’

Zimmer Biomet reported strong third-quarter 2026 results, with net sales exceeding expectations and a 3.7% constant currency growth. The company raised its full-year organic constant currency sales growth guidance to 3.0%-3.5% and adjusted EPS to $8.50-$8.60, marking the second raise this year. CEO Ivan Tornos highlighted the accelerated timeline for the Monogram robotic system's FDA submission and anticipated launch of a fully autonomous version in 1H 2027, ahead of schedule, projecting 2027 to be a better year for the company.